Stablepharma has partnered with a WHO pre-qualified European vaccine manufacturer as well as world-class UK academic institutions, in order to advance our work on the thermo-stabilisation of T&D containing vaccines and mRNA vaccine technologies. Stablepharma was delighted to received an Innovate UK grant to progress our work in these areas.

Projects and strategic partnerships

Stablepharma has a strategic R&D and commercialization partnership agreement in place with the European vaccine manufacturer BB-NCIPD Ltd (Bul Bio) with the aim to produce the world’s first ‘fridge free’ StablevaX™ Td vaccine.

We have established partnerships with two leading UK Universities, one to conduct our First in Human Clinical Trials for the Td vaccine, and the other to progress our mRNA stablisation project for Covid-19 vaccines.

Working with the UK’s The National Institute for Biological Standards and Control (NIBSC) to conduct animal trials we confirmed that the StablevaX™ tetanus vaccine to induce the same level of antibody response as the positive control vaccine.

Innovate UK is currently providing grant funding to Stablepharma to progress the R&D and product development work for the StablevaX™ Td vaccine.

Our white paper

StablevaX™ - a complementary technology for COVID-19 vaccines

In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never appeared starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.

StablevaX™ - a complementary technology for COVID-19 vaccines
Our white paper

Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose

A world changing invention for the stabilisation of vaccines.

Illustrative Examples of Extraordinary stability of vaccines when dried in Trehalose